Home LumiThera Inc.

LumiThera Inc.

    First Patient in the U.S. Multi-Center Enrolled in LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration

    The randomized, multi-center study called LIGHTSITE III enrolled and treated the first patient at Cumberland Valley Retina in Hagerstown, Maryland. The United States study is being conducted in leading retinal centers throughout the United States. The study will enroll approximately 100 patients suffering from dry AMD and treat them over the course of two years. In addition to demonstrating safety, key efficacy endpoints include visual acuity, contrast sensitivity and reduction of drusen deposits.

    LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy

    12/11/18: "Our new exciting partnership with LumiThera is fully consistent with the strategy and growth objectives of Miloftalmica, combining innovation and excellence in technology. LumiThera's breakthrough light delivery system is a value added to Miloftalmica's product portfolio," stated Andrea Pagani, Miloftalmica CEO.

    LumiThera LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark

    6/22/18: "It is very exciting to see the development of PBM treatment for dry AMD patients," stated Samuel Markowitz, M.D., Department of Ophthalmology and Vision Sciences, University of Toronto.

    RECENT COMMENTS